Human papillomavirus vaccine and men: What are the obstacles and challenges?

Nathan Stupiansky, Andreia B. Alexander, Gregory Zimet

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The present review describes the indications for vaccinating men with the quadrivalent human papillomavirus (HPV) vaccine, reports on the US rates of male vaccination, and reviews the recent research on acceptability of vaccinating men and research on the cost-effectiveness of adding men to existing female HPV immunization programs. RECENT FINDINGS: Recent evidence shows that the quadrivalent HPV vaccine prevents several HPV-related diseases in men. However, despite the licensure of the vaccine in the USA for men 9 through 26 years of age, rates of male vaccination are very low. Research on acceptability, in general, indicates strong interest in vaccination among men, parents, and healthcare providers, though female vaccination is typically seen as a higher priority. Cost-effectiveness studies indicate that in the context of modest female vaccination rates and with the specification of a broad range of disease outcomes (e.g. genital warts, anogenital cancers, and oropharyngeal cancers), male vaccination can be quite cost-effective. SUMMARY: Men are at high risk for HPV infection and can benefit from vaccination, but vaccination rates among men remain extremely low. More research needs to be done on the predictors of uptake of HPV vaccine among men and on the development of interventions to increase male vaccination.

Original languageEnglish
Pages (from-to)86-91
Number of pages6
JournalCurrent Opinion in Infectious Diseases
Volume25
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Papillomavirus Vaccines
Vaccination
Research
Cost-Benefit Analysis
Oropharyngeal Neoplasms
Condylomata Acuminata
Immunization Programs
Papillomavirus Infections
Licensure
Health Personnel
Vaccines
Parents
Costs and Cost Analysis

Keywords

  • Human papillomavirus
  • Men
  • Vaccine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Human papillomavirus vaccine and men : What are the obstacles and challenges? / Stupiansky, Nathan; Alexander, Andreia B.; Zimet, Gregory.

In: Current Opinion in Infectious Diseases, Vol. 25, No. 1, 02.2012, p. 86-91.

Research output: Contribution to journalArticle

@article{8d984e6a075d4ee5bebc306c933fb00b,
title = "Human papillomavirus vaccine and men: What are the obstacles and challenges?",
abstract = "PURPOSE OF REVIEW: The present review describes the indications for vaccinating men with the quadrivalent human papillomavirus (HPV) vaccine, reports on the US rates of male vaccination, and reviews the recent research on acceptability of vaccinating men and research on the cost-effectiveness of adding men to existing female HPV immunization programs. RECENT FINDINGS: Recent evidence shows that the quadrivalent HPV vaccine prevents several HPV-related diseases in men. However, despite the licensure of the vaccine in the USA for men 9 through 26 years of age, rates of male vaccination are very low. Research on acceptability, in general, indicates strong interest in vaccination among men, parents, and healthcare providers, though female vaccination is typically seen as a higher priority. Cost-effectiveness studies indicate that in the context of modest female vaccination rates and with the specification of a broad range of disease outcomes (e.g. genital warts, anogenital cancers, and oropharyngeal cancers), male vaccination can be quite cost-effective. SUMMARY: Men are at high risk for HPV infection and can benefit from vaccination, but vaccination rates among men remain extremely low. More research needs to be done on the predictors of uptake of HPV vaccine among men and on the development of interventions to increase male vaccination.",
keywords = "Human papillomavirus, Men, Vaccine",
author = "Nathan Stupiansky and Alexander, {Andreia B.} and Gregory Zimet",
year = "2012",
month = "2",
doi = "10.1097/QCO.0b013e32834ed5be",
language = "English",
volume = "25",
pages = "86--91",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Human papillomavirus vaccine and men

T2 - What are the obstacles and challenges?

AU - Stupiansky, Nathan

AU - Alexander, Andreia B.

AU - Zimet, Gregory

PY - 2012/2

Y1 - 2012/2

N2 - PURPOSE OF REVIEW: The present review describes the indications for vaccinating men with the quadrivalent human papillomavirus (HPV) vaccine, reports on the US rates of male vaccination, and reviews the recent research on acceptability of vaccinating men and research on the cost-effectiveness of adding men to existing female HPV immunization programs. RECENT FINDINGS: Recent evidence shows that the quadrivalent HPV vaccine prevents several HPV-related diseases in men. However, despite the licensure of the vaccine in the USA for men 9 through 26 years of age, rates of male vaccination are very low. Research on acceptability, in general, indicates strong interest in vaccination among men, parents, and healthcare providers, though female vaccination is typically seen as a higher priority. Cost-effectiveness studies indicate that in the context of modest female vaccination rates and with the specification of a broad range of disease outcomes (e.g. genital warts, anogenital cancers, and oropharyngeal cancers), male vaccination can be quite cost-effective. SUMMARY: Men are at high risk for HPV infection and can benefit from vaccination, but vaccination rates among men remain extremely low. More research needs to be done on the predictors of uptake of HPV vaccine among men and on the development of interventions to increase male vaccination.

AB - PURPOSE OF REVIEW: The present review describes the indications for vaccinating men with the quadrivalent human papillomavirus (HPV) vaccine, reports on the US rates of male vaccination, and reviews the recent research on acceptability of vaccinating men and research on the cost-effectiveness of adding men to existing female HPV immunization programs. RECENT FINDINGS: Recent evidence shows that the quadrivalent HPV vaccine prevents several HPV-related diseases in men. However, despite the licensure of the vaccine in the USA for men 9 through 26 years of age, rates of male vaccination are very low. Research on acceptability, in general, indicates strong interest in vaccination among men, parents, and healthcare providers, though female vaccination is typically seen as a higher priority. Cost-effectiveness studies indicate that in the context of modest female vaccination rates and with the specification of a broad range of disease outcomes (e.g. genital warts, anogenital cancers, and oropharyngeal cancers), male vaccination can be quite cost-effective. SUMMARY: Men are at high risk for HPV infection and can benefit from vaccination, but vaccination rates among men remain extremely low. More research needs to be done on the predictors of uptake of HPV vaccine among men and on the development of interventions to increase male vaccination.

KW - Human papillomavirus

KW - Men

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84155163104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155163104&partnerID=8YFLogxK

U2 - 10.1097/QCO.0b013e32834ed5be

DO - 10.1097/QCO.0b013e32834ed5be

M3 - Article

C2 - 22143118

AN - SCOPUS:84155163104

VL - 25

SP - 86

EP - 91

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 1

ER -